Oncologie [Advances in Oncology 2019]

Details

Ressource 1Download: RMS_676-7_72.pdf (122.94 [Ko])
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_66705C7E0EE3
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Oncologie [Advances in Oncology 2019]
Journal
Revue medicale suisse
Author(s)
Vernadou A., Ferahta N., Mederos N., Ferraro D., Dischl-Antonioni I., Diciolla A., Liapi A., Mosimann V., Latifyan S., Aedo-Lopez V., Berthold D., Digklia A., Michielin O., Montemurro M., Wagner A.D., Zaman K., Peters S., Stravodimou A., Sarivalasis A.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
15/01/2020
Peer-reviewed
Oui
Volume
16
Number
676-7
Pages
72-77
Language
french
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
Driven by highly specialized medicine, research and the quest for personalization of treatments, oncology witnessed substantial advances in 2019. This year numerous treatments have consolidated their importance and broadened their indications. Multiple innovative treatments, currently under study, brought hope for future advances, while biomarkers, such as PD-L1, microsatellite instability (MSI), tumor mutational burden (TMB), BRCA1/2 gene mutations, and homologous recombination deficiency (HRD) allowed better selection and customization of available treatments. This article provides an overview of this year's advances in oncology.
Keywords
Biomarkers, Tumor, Humans, Mutation, Neoplasms/diagnosis, Neoplasms/therapy
Pubmed
Create date
24/08/2021 10:37
Last modification date
20/08/2022 6:11
Usage data